Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.1 USD | 0.00% | +1.85% | -24.14% |
Sales 2024 * | 149M 11.96B | Sales 2025 * | 192M 15.38B | Capitalization | 193M 15.44B |
---|---|---|---|---|---|
Net income 2024 * | -16M -1.28B | Net income 2025 * | 18M 1.44B | EV / Sales 2024 * | 1.29 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1 x |
P/E ratio 2024 * |
-12.6
x | P/E ratio 2025 * |
12.9
x | Employees | 147 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.89% |
Latest transcript on Rigel Pharmaceuticals, Inc.
1 week | +1.85% | ||
Current month | -25.68% | ||
1 month | -22.54% | ||
3 months | -14.73% | ||
6 months | +48.11% | ||
Current year | -24.14% |
Managers | Title | Age | Since |
---|---|---|---|
Raul Rodriguez
CEO | Chief Executive Officer | 63 | 31/03/00 |
Dean Schorno
DFI | Director of Finance/CFO | 61 | 28/05/18 |
Chief Tech/Sci/R&D Officer | - | 31/08/16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Gregg Lapointe
CHM | Chairman | 65 | 01/11/17 |
Gary Lyons
BRD | Director/Board Member | 73 | 30/09/05 |
Raul Rodriguez
CEO | Chief Executive Officer | 63 | 31/03/00 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.02% | 509 M€ | -.--% | ||
0.02% | 0 M€ | 0.00% | - | |
0.00% | 9 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 1.1 | 0.00% | 364,286 |
25/04/24 | 1.1 | -2.22% | 2,972,822 |
24/04/24 | 1.125 | -1.32% | 6,450,770 |
23/04/24 | 1.14 | +0.88% | 520,000 |
22/04/24 | 1.13 | +4.63% | 3,339,868 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-24.14% | 193M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- RIGL Stock